A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Name: A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Published: 2026
License: Public Domain

Sun Yat-sen University · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

immune-checkpoint-inhibitors

recurrent/metastatic head and neck squamous cell carcinoma, r/m hnscc, second-line therapy, immune checkpoint inhibitors, salvage therapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Related documents